These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2279 related articles for article (PubMed ID: 29144791)
1. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224 [TBL] [Abstract][Full Text] [Related]
3. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330 [TBL] [Abstract][Full Text] [Related]
4. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
5. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
6. Current Microsatellite Instability Testing in Management of Colorectal Cancer. Sun BL Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812 [TBL] [Abstract][Full Text] [Related]
7. Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Copija A; Waniczek D; Witkoś A; Walkiewicz K; Nowakowska-Zajdel E Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067827 [TBL] [Abstract][Full Text] [Related]
8. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Battaglin F; Naseem M; Lenz HJ; Salem ME Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589 [TBL] [Abstract][Full Text] [Related]
10. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077 [TBL] [Abstract][Full Text] [Related]
12. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663 [TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review. Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Link JT; Overman MJ Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597 [TBL] [Abstract][Full Text] [Related]
15. The impact of microsatellite stability status in colorectal cancer. Gupta R; Sinha S; Paul RN Curr Probl Cancer; 2018 Nov; 42(6):548-559. PubMed ID: 30119911 [TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842 [TBL] [Abstract][Full Text] [Related]
17. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
18. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time? Søreide K Tumour Biol; 2007; 28(5):290-300. PubMed ID: 17962726 [TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability testing and its role in the management of colorectal cancer. Kawakami H; Zaanan A; Sinicrope FA Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544 [TBL] [Abstract][Full Text] [Related]
20. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Zhao P; Li L; Jiang X; Li Q J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]